VPTDF
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model of the heart chamber using echocardiograms and magnetic resonance imaging images; and obtain reproducible, accurate volumetric measurement, and ejection fraction. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and Covid-19 related heart issues. The company was incorporated in 2004 and is based in Toronto, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.00 | $4,300 | -$598,881 |
| 2025 Q3 | -0.00 | $104,304 | -$68,712 |
| 2025 Q2 | -0.01 | $0 | -$547,331 |
| 2025 Q1 | -0.01 | $71,320 | -$312,522 |
| 2024 Q4 | -0.01 | $0 | -$720,814 |
| 2024 Q3 | -0.01 | $64,507 | -$691,153 |
| 2024 Q2 | -0.01 | $30,665 | -$1M |
| 2024 Q1 | -0.01 | $0 | -$873,256 |